Condition: Myelodysplastic Syndromes, de Novo · Myelodysplastic Syndromes, Secondary · Myelodysplastic Syndromes, Previously Treated · Sponsor: Andrew E. Place, MD
This trial is evaluating the safety and tolerability of venetoclax with chemotherapy in pediatric and young adult patients with hematologic malignancies, including myelodysplastic syndrome (MDS), acute myeloid leukemia derived from myelodysplastic syndrome (MDS/AML), and acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LBL). The names of the study drugs involved in this study are below. Please note this is a list for the study as a whole, participants will receive drugs according to disease cohort. * Venetoclax * Azacitidine * Cytarabine * Methotrexate * Hydrocortisone * Leucovorin * Dexamethasone * Vincristine * Doxorubicin * Dexrazoxane * Calaspargase pegol * Hydrocortisone
This description comes directly from the study's public registry record.
Andrew E Place, MD, PhD · 617-632-2313 · andrew_place@dfci.harvard.edu
Jessica A Pollard, MD, PhD · 617-632-4321 · Jessica_Pollard@dfci.harvard.edu
Always discuss trial participation with your own doctor first.
| University of California San Francisco-Benioff Children's Hospital | San Francisco, California, United States | Recruiting |
| Children's Hospital Colorado | Aurora, Colorado, United States | Recruiting |
| Children's Healthcare of Atlanta at Arthur M. Blank Hospital | Atlanta, Georgia, United States | Recruiting |
| Ann & Robert H Lurie Children's Hospital of Chicago | Chicago, Illinois, United States | Recruiting |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05292664